Hypothetical Patient Profiles

Based on characteristics of patients included in PALOMA-2
Click on the patient you would like to learn more about.

ibrance-aromatase-inhibitor-page-accordion-1

Why consider IBRANCE + aromatase inhibitor first line in mBC?
MEDICAL HISTORY
Initially diagnosed with breast cancer >8 years ago
  • Treatment for eBC: lumpectomy, radiation, 5 years of anastrozole
  • 3-year disease-free interval
Complaint: Mild hip pain
  • ECOG performance status 0
  • Workup: bone scan reveals metastases
Diagnosis: Postmenopausal ER+/HER2- mBC
How Evelyn aligns with patients in PALOMA-21
eBC=early breast cancer; ECOG=Eastern Cooperative Oncology Group; ER=estrogen receptor.

ibrance-aromatase-inhibitor-page-accordion-2

Why consider IBRANCE + aromatase inhibitor first line in mBC?
MEDICAL HISTORY
Initially diagnosed with breast cancer 6 years ago
  • Treatment for eBC: right modified radical mastectomy, chemotherapy, 5 years of anastrozole
  • 15-month disease-free interval
Complaint: Mild dry cough on exercise without fever
  • ECOG performance status 1
  • Workup: MRI detected metastases in the liver and lung
Diagnosis: Postmenopausal ER+/HER2- mBC
How Brenda aligns with patients in PALOMA-21
eBC=early breast cancer; ECOG=Eastern Cooperative Oncology Group; ER=estrogen receptor; MRI=magnetic resonance imaging.
*Not an actual patient.
REFERENCE
1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-1936.